Tetracosactide

Cosacthen

0.25 MG / ML SolutionCanadaMarketedAuthorised 13 Oct 2020

Open in the registerAsk Osler about it

This is a veterinary medicine.

In other countries

The same active substances on other registers, the same brand first.

Nuvacthen Depot 1MG/ML Suspensión InyectableSpain · 1 mg · suspensión inyectable · Alfasigma S.P.A.Same substance
SynacthenItaly · Soluzione iniettabile · Alfasigma S.P.A.Same substance
Synacthen 0,25 mg/ml, oplossing voor injectie of infusieNetherlands · Oplossing voor injectie of infusie · Alfasigma S.p.A.Same substance
Synacthen DepotSaudi Arabia · Hafslund Nycomid PharmaSame substance
Synacthen DepotSaudi Arabia · TAKEDA AUSTRIA GmbHSame substance

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Tetracosactide

Cosacthen

0.25 MG / ML SolutionCanadaMarketedAuthorised 13 Oct 2020

Open in the registerAsk Osler about it

This is a veterinary medicine.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Tetracosactide
Strength: 0.25 MG / ML
Dosage form: Solution
Route: Intramuscular, Intravenous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 13 Oct 2020
Registration: DIN 02498405
Marketing authorisation holder: Dechra LTD
Supply: PRESCRIPTION